158 related articles for article (PubMed ID: 22430871)
1. A weekly combination of carboplatin and irinotecan for previously untreated extensive disease small-cell lung cancer, results of a minimum follow-up of 3 years: a multi-center Phase II trial JMTO LC02-02.
Okishio K; Mio T; Kawahara M; Yoshioka H; Yanagihara K; Daimon T; Furuse K
Jpn J Clin Oncol; 2012 May; 42(5):387-93. PubMed ID: 22430871
[TBL] [Abstract][Full Text] [Related]
2. A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.
Misumi Y; Nishio M; Takahashi T; Ohyanagi F; Horiike A; Murakami H; Kenmotsu H; Yamamoto N; Ishii M; Shimokawa T; Hida N; Okamoto H
Jpn J Clin Oncol; 2014 Feb; 44(2):116-21. PubMed ID: 24338555
[TBL] [Abstract][Full Text] [Related]
3. A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.
Okamoto H; Naoki K; Narita Y; Hida N; Kunikane H; Watanabe K
Lung Cancer; 2006 Aug; 53(2):197-203. PubMed ID: 16781005
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer.
Sohn JH; Choi HJ; Chang J; Kim SK; Lee CG; Chung KY; Kim DJ; Cho BC; Shin SJ; Moon YW; Kim JH
Lung Cancer; 2006 Dec; 54(3):365-70. PubMed ID: 17011068
[TBL] [Abstract][Full Text] [Related]
5. Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study.
Ishimoto O; Sugawara S; Inoue A; Maemondo M; Nukiwa T
Respir Investig; 2015 Jul; 53(4):156-60. PubMed ID: 26100175
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of paclitaxel, carboplatin, and topotecan with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: Southwest Oncology Group 9914.
Hesketh PJ; McCoy J; Dunphy FR; Bearden JD; Weiss GR; Giguere JK; Atkins JN; Dakhil SR; Kelly K; Crowley JJ; Gandara DR
J Thorac Oncol; 2006 Nov; 1(9):991-5. PubMed ID: 17409984
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of a 3-week schedule of irinotecan combined with cisplatin in previously untreated extensive-stage small-cell lung cancer.
Lee JE; Park HS; Jung SS; Kim JO; Kim SY
Oncology; 2007; 73(1-2):76-80. PubMed ID: 18334853
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
Hirose T; Horichi N; Ohmori T; Ogura K; Hosaka T; Ando K; Ishida H; Noguchi H; Adachi M
Lung Cancer; 2003 Jun; 40(3):333-8. PubMed ID: 12781433
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Zubkus JD; Murphy PB; Saez RA; Farley C; Yardley DA; Burris HA; Hainsworth JD
J Thorac Oncol; 2009 Dec; 4(12):1555-60. PubMed ID: 19875975
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
Laack E; Thöm I; Krüll A; Engel-Riedel W; Müller T; Meissner C; Dürk H; Fischer J; Gütz S; Kortsik C; Elbers M; Schuch G; Andritzky B; Görn M; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C
Lung Cancer; 2007 Aug; 57(2):181-6. PubMed ID: 17442447
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy with irinotecan and cisplatin in elderly patients (>or= 65 years) with extensive-disease small-cell lung cancer.
Kim HG; Lee GW; Kang JH; Kang MH; Hwang IG; Kim SH; Hahm JR; Jeong YY; Kim HC; Lee JD; Lee JS; Hwang YS
Lung Cancer; 2008 Aug; 61(2):220-6. PubMed ID: 18272249
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
Kim HS; Kim JH; Kim B; Choi HC; Kwon JH; Choi DR
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1591-7. PubMed ID: 23568282
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with Eastern Cooperative Oncology Group Performance Status of 2, or age > or = 70 years.
Neubauer M; Schwartz J; Caracandas J; Conkling P; Ilegbodu D; Tuttle T; Asmar L
J Clin Oncol; 2004 May; 22(10):1872-7. PubMed ID: 15143079
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Rossman J; Reddy V; Cantor A; Miley D; Robert F
Lung Cancer; 2011 May; 72(2):219-23. PubMed ID: 20934233
[TBL] [Abstract][Full Text] [Related]
16. Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Spigel DR; Hainsworth JD; Simons L; Meng C; Burris HA; Yardley DA; Grapski R; Schreeder M; Mallidi PV; Greco FA;
J Thorac Oncol; 2007 Sep; 2(9):854-61. PubMed ID: 17805064
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Fukuda M; Oka M; Soda H; Kinoshita A; Fukuda M; Nagashima S; Kuba M; Takatani H; Tsurutani J; Nakamura Y; Kasai T; Inoue Y; Soejima Y; Kohno S;
Cancer Chemother Pharmacol; 2004 Dec; 54(6):573-7. PubMed ID: 15365766
[TBL] [Abstract][Full Text] [Related]
18. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study.
Charpidou A; Tsagouli S; Tsimpoukis S; Vassias A; Makrilia N; Stratakos G; Gkiozos I; Syrigos K
Anticancer Drugs; 2010 Jul; 21(6):651-5. PubMed ID: 20386306
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of cisplatin and irinotecan alternating with doxorubicin, cyclophosphamide and etoposide in previously untreated patients with extensive-disease small-cell lung cancer.
Tabata M; Kiura K; Okimoto N; Segawa Y; Shinkai T; Yonei T; Kuyama S; Harita S; Hotta K; Ueoka H; Tanimoto M
Cancer Chemother Pharmacol; 2007 Jun; 60(1):1-6. PubMed ID: 17393168
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study.
Briasoulis E; Golfinopoulos V; Karina M; Papakostas P; Pavlidis N; Fountzilas G
Anticancer Drugs; 2010 Sep; 21(8):785-9. PubMed ID: 20647930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
